Evidence mapPaperPMID 37600689Full record

ReviewFrontiers in endocrinology2023

Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives.

Yu Wang, Mingyue Jin, Chak Kwong Cheng, Qiang Li

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 74 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1-Mediated Glucotoxic Stress in Diabetic Kidney Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Inflammation and Diabetic Kidney Disease.International journal of molecular sciences · 2026
    Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Yu WangDepartment of Endocrinology and Metabolism, Shenzhen University General Hospital, Shenzhen, Guangdong, China.
Mingyue JinDepartment of Endocrinology and Metabolism, Shenzhen University General Hospital, Shenzhen, Guangdong, China.
Chak Kwong ChengSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Qiang LiDepartment of Endocrinology and Metabolism, Shenzhen University General Hospital, Shenzhen, Guangdong, China.
Shenzhen University · CNChinese University of Hong Kong · HKCity University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is a chronic complication of diabetes and the leading cause of end-stage renal disease (ESRD) worldwide. Currently, there are limited therapeutic drugs available for DKD. While previous research has primarily focused on glomerular injury, recent studies have increasingly emphasized the role of renal tubular injury in the pathogenesis of DKD. Various factors, including hyperglycemia, lipid accumulation, oxidative stress, hypoxia, RAAS, ER stress, inflammation, EMT and programmed cell death, have been shown to induce renal tubular injury and contribute to the progression of DKD. Additionally, traditional hypoglycemic drugs, anti-inflammation therapies, anti-senescence therapies, mineralocorticoid receptor antagonists, and stem cell therapies have demonstrated their potential to alleviate renal tubular injury in DKD. This review will provide insights into the latest research on the mechanisms and treatments of renal tubular injury in DKD.

Indexed as

Diabetes MellitusDiabetic NephropathiesHyperglycemiaKidney Failure, ChronicApoptosisHumansHypoglycemic AgentsHypoglycemic Agentsdiabetic kidney diseasemechanismprogrammed cell deathstem celltherapytubular injury

Identifiers

PMID37600689
PMCPMC10433744
OpenAlexW4385493107

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.